1. A multi-arm proof of concept study of adjunctive host-directed TB therapy (TB HDT).
2. Treatment outcomes, PK and safety of a six month TB treatment regimen with once weekly high dose rifapentine and moxifloxacin in the continuation phase, in HIV-infected patients on ART.
3. Rapid detection of acquired fluoroquinolone hetero-resistance (FQ-R) in MDR-TB.
4. Imatinib dose selection for DR-TB.
5. γ9δ2 T cell protection against TB infection.